Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I)

Table 1 Assessment schedule.

Study Phase	LTx		EOT	Post-Treatment Phase						Follow-Up
Visit no.	1	2	3	4	5-9	10	11	12	13	14	15	16	17
Study days	1	2	3	4	5-9	10	14	20	30 ± 10 d	90 ± 30 d	180 ± 30 d	270 ± 30 d	365 ± 30 d
MAPC treatment	X		X
DLT assessment	X	X	X	X		X			X
Laboratory	X	X	X	X	X	X	X	X	X	X	X	X	X
Doppler ultrasound	X	X	X	X		X			X	X			X
Liver biopsy	X			X		X
Immunomonitoring	X		X			X			X				X

ISSN: 1479-5876